Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Chiome Bioscience Inc. ( (JP:4583) ) is now available.
Chiome Bioscience Inc. announced the publication of results from the first part of its CBA-1205 Phase I clinical study in the journal Cancer Science. The study, involving 22 patients with solid tumors, demonstrated high safety and potential efficacy, with a notable case of a melanoma patient experiencing stable disease for over three years. The results highlight CBA-1205’s promise, especially in melanoma, and indicate DLK1 levels as a potential biomarker for its efficacy, prompting further study and patient enrollment in the next phase of trials.
More about Chiome Bioscience Inc.
Chiome Bioscience Inc. operates in the biotechnology industry, focusing on developing innovative monoclonal antibody therapies. The company is particularly engaged in advancing treatments for cancer, with its proprietary technology Glymax® enhancing antibody activity.
YTD Price Performance: -13.75%
Average Trading Volume: 12,030,205
Technical Sentiment Consensus Rating: Sell
Current Market Cap: Yen15.54B
Find detailed analytics on 4583 stock on TipRanks’ Stock Analysis page.